SCHOTT Pharma KGaA (1SXP) Resumen de Acciones
SCHOTT Pharma AG & Co. KGaA desarrolla, fabrica y vende soluciones de contención de medicamentos y sistemas de administración de fármacos inyectables para las industrias farmacéutica, biotecnológica y de ciencias de la vida de todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 5/6 |
| Dividendos | 1/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en 1SXP a partir de nuestros controles de riesgos.
1SXP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeCompetidores de SCHOTT Pharma AG & Co. KGaA
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €14.94 |
| Máximo en las últimas 52 semanas | €30.25 |
| Mínimo de 52 semanas | €12.62 |
| Beta | 0.89 |
| Cambio en 1 mes | 9.05% |
| Variación en 3 meses | 5.66% |
| Cambio de 1 año | -41.41% |
| Variación en 3 años | n/a |
| Variación en 5 años | n/a |
| Variación desde la OPV | -52.27% |
Noticias y actualizaciones recientes
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).1SXP: Dividend Policy And 2026 Guidance Will Support Future Profitability
Analysts have adjusted their price target for SCHOTT Pharma KGaA to €19.23 from €22.97, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, with the company expecting revenue growth at constant currencies of 2 to 5% (Corporate guidance).
1SXP: Dividend And 2026 Earnings Guidance Will Support Confidence In Undervalued Shares
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €25.90, indicating relatively unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E in their updated models. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed its earnings guidance for the 2026 financial year, expecting revenue growth at constant currencies of 2 to 5% (company guidance).1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares
Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.1SXP: Dividend And Mid Term Outlook Will Support Confidence In Undervalued Shares
Analysts have maintained their €25.90 price target for SCHOTT Pharma KGaA, citing only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that they view as too small to change their overall assessment. What's in the News SCHOTT Pharma confirmed earnings guidance for the 2026 financial year, reiterating its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).1SXP: Dividend Initiation Will Support Confidence In Updated Mid Term Outlook
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly lower from €26.00 to €25.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Annual General Meeting on February 3, 2026 approved a dividend of €0.18 per share, with a payout ratio of 18% of consolidated net income (company announcement).Recent updates
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).1SXP: Dividend Policy And 2026 Guidance Will Support Future Profitability
Analysts have adjusted their price target for SCHOTT Pharma KGaA to €19.23 from €22.97, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, with the company expecting revenue growth at constant currencies of 2 to 5% (Corporate guidance).1SXP: Dividend And 2026 Earnings Guidance Will Support Confidence In Undervalued Shares
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €25.90, indicating relatively unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E in their updated models. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed its earnings guidance for the 2026 financial year, expecting revenue growth at constant currencies of 2 to 5% (company guidance).1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares
Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.1SXP: Dividend And Mid Term Outlook Will Support Confidence In Undervalued Shares
Analysts have maintained their €25.90 price target for SCHOTT Pharma KGaA, citing only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that they view as too small to change their overall assessment. What's in the News SCHOTT Pharma confirmed earnings guidance for the 2026 financial year, reiterating its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).1SXP: Dividend Initiation Will Support Confidence In Updated Mid Term Outlook
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly lower from €26.00 to €25.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Annual General Meeting on February 3, 2026 approved a dividend of €0.18 per share, with a payout ratio of 18% of consolidated net income (company announcement).SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 14
1SXP: Fair Outlook Will Balance Dividend Payout With Leadership Transition
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €14.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that they see as balancing out overall. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, payable on February 6, 2026, with an ex date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
Feb 021SXP: Dividend Initiation Will Support Confidence In Revised Long Term Outlook
Analysts have reduced their price target for SCHOTT Pharma KGaA from €36.00 to €26.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which point to a more conservative outlook on the shares' fair value. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, an ex dividend date on February 4, 2026, and a record date on February 5, 2026 (Key Developments).1SXP: Leadership Transition And Dividend Policy Will Support Future Profitability
Analysts have trimmed their fair value estimate for SCHOTT Pharma KGaA from €28.28 to €22.97, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple as key drivers of the change. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, ex-date on February 4, 2026, and record date on February 5, 2026 (Key Developments).1SXP Outlook Will Balance Lower Expectations With Dividend And Leadership Transition
Analysts have reduced their price target on SCHOTT Pharma KGaA from €22.00 to €14.00, reflecting tempered expectations for revenue growth, profit margins, and future valuation multiples in an environment characterized by higher discount rates. What's in the News SCHOTT Pharma AG & Co. KGaA declared an annual dividend of EUR 0.18 per share, payable on February 6, 2026, with an ex-dividend date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
Dec 151SXP: Leadership Transition Will Support Future Profitability And Operational Discipline
Analysts have modestly reduced their price target for SCHOTT Pharma KGaA by approximately €0.90. This reflects slightly lower assumptions for revenue growth, profit margins, and future valuation multiples, alongside a marginally higher discount rate.A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Nov 241SXP: Leadership Transition Will Drive Renewed Operational Focus And Profitability
Analysts have modestly lowered their price target for SCHOTT Pharma KGaA from €29.33 to €29.19, citing slight reductions in anticipated revenue growth and profit margins, as well as a higher discount rate used in their updated valuation models. What's in the News Christian Mias appointed as CEO of SCHOTT Pharma KGaA.Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Nov 02Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
Sep 19Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Aug 15These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Jul 19Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
Jun 13Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 18An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Apr 27We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Mar 22SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
Feb 12Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Jan 13
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Nov 25SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
Oct 27SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Sep 01Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Aug 07Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
Jul 01We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Jun 07Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Mar 28Rentabilidad de los accionistas
| 1SXP | DE Life Sciences | Mercado DE | |
|---|---|---|---|
| 7D | 0.5% | -0.5% | -0.9% |
| 1Y | -41.4% | -19.7% | -0.9% |
Rentabilidad vs. Industria: Los resultados de 1SXP fueron inferiores a los de la industria German Life Sciences, que obtuvo un rendimiento del -19.7% el año pasado.
Rentabilidad vs. Mercado: 1SXP obtuvo unos resultados inferiores a los del mercado German, que fueron del -0.9% el año pasado.
Volatilidad de los precios
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Precio estable de las acciones: 1SXP no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 1SXP (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1884 | 4,829 | Christian Mias | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA desarrolla, fabrica y vende soluciones de contención de fármacos y sistemas de administración de fármacos inyectables para las industrias farmacéutica, biotecnológica y de ciencias de la vida de todo el mundo. La empresa ofrece jeringuillas precargables de vidrio o polímero, viales de vidrio, cartuchos y ampollas. Sus productos de jeringuillas incluyen syriQ, una jeringuilla de vidrio para vacunas; syriQ BioPure, una jeringuilla de vidrio para productos biológicos; syriQ BioPure silicone-free, una jeringuilla de vidrio precargable y sin silicona para productos biológicos; SCHOTT TOPPAC, una jeringuilla de polímero; SCHOTT TOPPAC cosmetic, una jeringuilla de polímero para tratamientos estéticos; SCHOTT TOPPAC freeze, una jeringa de polímero para aplicaciones de frío profundo; SCHOTT TOPPAC sensitive, una jeringa de polímero para fármacos sensibles; SCHOTT TOPPAC infuse, una jeringa de polímero para terapia de infusión; y SCHOTT TOPPAC unique, un contenedor de polímero.
Resumen de fundamentos de SCHOTT Pharma AG & Co. KGaA
| Estadísticas fundamentales de 1SXP | |
|---|---|
| Capitalización bursátil | €2.25b |
| Beneficios(TTM) | €149.95m |
| Ingresos (TTM) | €995.03m |
¿Está 1SXP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 1SXP | |
|---|---|
| Ingresos | €995.03m |
| Coste de los ingresos | €660.29m |
| Beneficio bruto | €334.74m |
| Otros gastos | €184.80m |
| Beneficios | €149.95m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
May 13, 2026
| Beneficios por acción (BPA) | 1.00 |
| Margen bruto | 33.64% |
| Margen de beneficio neto | 15.07% |
| Ratio deuda/patrimonio | 28.8% |
¿Cómo se ha desempeñado 1SXP a largo plazo?
Ver rendimiento histórico y comparativaDividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/05 23:42 |
| Precio de las acciones al final del día | 2026/05/05 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/09/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
SCHOTT Pharma AG & Co. KGaA está cubierta por 22 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Jonathon Unwin | Barclays |